NexEye, which recently debuted on the KOSDAQ, is experiencing a significant decline on its first day of trading, falling below its initial public offering price.
According to the Korea Exchange, as of 9:20 a.m. on November 12, NexEye's shares were trading at 5,920 won, down 26.00% from the IPO price of 8,000 won. The stock opened more than 2,000 won below the offering price, indicating a weak start.
Founded in 2021, NexEye is a research and development company focused on natural sciences and engineering, primarily engaged in developing new drugs in the immuno-oncology sector. The company aims to identify the causes of non-responsiveness to existing immuno-oncology treatments and develop new cancer therapies targeting these issues.
NexEye is particularly focused on discovering and developing new drug candidates that can overcome the limitations of current treatments. Enhancing the therapeutic efficacy of immuno-oncology drugs is a key direction for the company's research and development efforts.
However, NexEye's business structure remains centered on research and development, posing challenges for profitability. Last year, the company reported operating revenue of 5.11 billion won but incurred an operating loss of 16.52 billion won.
Drug development companies typically face substantial costs during the research and development phase, with commercialization often taking a long time. Consequently, future research outcomes and the progress of commercialization are expected to be significant factors in assessing the company's value.
Korea Investment & Securities served as the lead underwriter for NexEye's KOSDAQ listing.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.